311 related articles for article (PubMed ID: 22169231)
1. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects.
Sabuncu MR; Buckner RL; Smoller JW; Lee PH; Fischl B; Sperling RA;
Cereb Cortex; 2012 Nov; 22(11):2653-61. PubMed ID: 22169231
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
3. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.
Martiskainen H; Helisalmi S; Viswanathan J; Kurki M; Hall A; Herukka SK; Sarajärvi T; Natunen T; Kurkinen KM; Huovinen J; Mäkinen P; Laitinen M; Koivisto AM; Mattila KM; Lehtimäki T; Remes AM; Leinonen V; Haapasalo A; Soininen H; Hiltunen M
J Alzheimers Dis; 2015; 43(2):565-73. PubMed ID: 25096612
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
5. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.
Nho K; Kim S; Horgusluoglu E; Risacher SL; Shen L; Kim D; Lee S; Foroud T; Shaw LM; Trojanowski JQ; Aisen PS; Petersen RC; Jack CR; Weiner MW; Green RC; Toga AW; Saykin AJ;
BMC Med Genomics; 2017 May; 10(Suppl 1):29. PubMed ID: 28589856
[TBL] [Abstract][Full Text] [Related]
6. Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.
Hayes JP; Logue MW; Sadeh N; Spielberg JM; Verfaellie M; Hayes SM; Reagan A; Salat DH; Wolf EJ; McGlinchey RE; Milberg WP; Stone A; Schichman SA; Miller MW
Brain; 2017 Mar; 140(3):813-825. PubMed ID: 28077398
[TBL] [Abstract][Full Text] [Related]
7. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
9. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
10. Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.
Darst BF; Koscik RL; Racine AM; Oh JM; Krause RA; Carlsson CM; Zetterberg H; Blennow K; Christian BT; Bendlin BB; Okonkwo OC; Hogan KJ; Hermann BP; Sager MA; Asthana S; Johnson SC; Engelman CD
J Alzheimers Dis; 2017; 55(2):473-484. PubMed ID: 27662287
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation and neuroimaging measures in Alzheimer disease.
Biffi A; Anderson CD; Desikan RS; Sabuncu M; Cortellini L; Schmansky N; Salat D; Rosand J;
Arch Neurol; 2010 Jun; 67(6):677-85. PubMed ID: 20558387
[TBL] [Abstract][Full Text] [Related]
12. Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.
Mecca AP; Barcelos NM; Wang S; Brück A; Nabulsi N; Planeta-Wilson B; Nadelmann J; Benincasa AL; Ropchan J; Huang Y; Gelernter J; Van Ness PH; Carson RE; van Dyck CH
Neurobiol Aging; 2018 Jan; 61():207-214. PubMed ID: 29111487
[TBL] [Abstract][Full Text] [Related]
13. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
[TBL] [Abstract][Full Text] [Related]
14. APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease.
Hohman TJ; Dumitrescu L; Oksol A; Wagener M; Gifford KA; Jefferson AL;
PLoS One; 2017; 12(11):e0188501. PubMed ID: 29190651
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.
Kim S; Swaminathan S; Shen L; Risacher SL; Nho K; Foroud T; Shaw LM; Trojanowski JQ; Potkin SG; Huentelman MJ; Craig DW; DeChairo BM; Aisen PS; Petersen RC; Weiner MW; Saykin AJ;
Neurology; 2011 Jan; 76(1):69-79. PubMed ID: 21123754
[TBL] [Abstract][Full Text] [Related]
16. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.
Gorijala P; Aslam MM; Dang LT; Xicota L; Fernandez MV; Sung YJ; Fan KH; Feingold E; Surace EI; Chhatwal JP; Hom CL; ; ; Hartley SL; Hassenstab J; Perrin RJ; Mapstone M; Zaman SH; Ances BM; Kamboh MI; Lee JH; Cruchaga C
Alzheimers Dement; 2024 Feb; 20(2):1038-1049. PubMed ID: 37855447
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
19. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
Wang ML; Wei XE; Yu MM; Li PY; Li WB;
Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
[TBL] [Abstract][Full Text] [Related]
20. Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Trojanowski JQ; Shaw LM; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
Neurology; 2010 Jul; 75(2):143-51. PubMed ID: 20625167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
